Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The previously reported SANET-ep trial (NCT02588170) demonstrated surufatinib significantly improves progression-free survival (PFS) in patients (pts) with advanced extrapancreatic neuroendocrine tumors (epNETs) compared to placebo; median PFS (9.2 vs. 3.8 months; HR = 0.334, 95% CI 0.223 to 0.499, p<0.0001).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Li J
Authors: Li J, Xu J, Zhou Z, Bai C, Chi Y,
Keywords: extra-pancreatic, neuroendocrine tumors, safety,
Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Dasari A, Paulson S, Sung M, Tucci C, Kauh J,
Keywords: Neuroendocrine Tumors, Pancreatic, Surufatinib,
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a low incidence and prevalence representing < 2% of all gastrointestinal tumors with a heterogeneous biological behavior and an often complex management.
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author:
Authors: Cabezas-Agricola J, Baron-Duarte F, Fernandez-Rodriguez E, Varo E, Cameselle-Teijeiro J,
Keywords: gastroenteropancreatic neuroendocrine tumors, ultrasound endoscopy, Ki-67,